Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
Drug guidance

Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer

Condition

Cancer

Breast

17 February 2025

Published on 17 Feb 2025
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended sacituzumab govitecan for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The decision was based on the unfavourable cost effectiveness of sacituzumab govitecan compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for sacituzumab govitecan are provided in the Annex.

Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer (17 Feb 2025) [PDF, 218 KB]

PES Sacituzumab govitecan for previously treated HR-positive, HER2-negative advanced breast cancer (17 Feb 2025) [PDF, 96 KB]

Back to top